Email ID
Password
Scrip   
Biocon taps HCG for antibody cervical cancer trials
15 December 2009
Anju Ghangurde

The Indian biotechnology company, Biocon, is to work with the HCG group of hospitals to study the potential benefits of Biocon's humanised monoclonal antibody, BIOMAb EGFR, in cervical cancer patients.

Other studies with BIOMAb EGFR, which targets the epidermal growth factor receptor (EGFR)...



Please Login to read the full article.
JOB OF THE WEEK Promote your vacancy here
© 2010 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36